A-024 Prognosis for Adverse Events in Suspected ACS Without MI, and Subgroups with or Without History of Incident and Previous MACE Using the Atellica IM High-Sensitivity Troponin I Assay

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Prospective analysis evaluated cTnI's ability to predict all-cause mortality and MACE among ACS patients, indicating potential risks ahead.

Patients with cTnI above the 99th percentile experienced significantly higher rates of all-cause mortality and major adverse cardiac events after one year.
Among the primary analysis population, 39.5% with high cTnI levels faced ACM/MACE compared to 12.9% with lower levels; aHR was 1.85 at 365 days.
This observational analysis incorporated 2,064 adult patients suspected of acute coronary syndrome across 29 U.S. sites from 2014 to 2016.
Highlighting the importance of baseline cTnI levels, findings suggest that monitoring may help identify higher-risk patients for adverse outcomes.

Snyder et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Prospective analysis evaluated cTnI's ability to predict all-cause mortality and MACE among ACS patients, indicating potential risks ahead.

Patients with cTnI above the 99th percentile experienced significantly higher rates of all-cause mortality and major adverse cardiac events after one year.
Among the primary analysis population, 39.5% with high cTnI levels faced ACM/MACE compared to 12.9% with lower levels; aHR was 1.85 at 365 days.
This observational analysis incorporated 2,064 adult patients suspected of acute coronary syndrome across 29 U.S. sites from 2014 to 2016.
Highlighting the importance of baseline cTnI levels, findings suggest that monitoring may help identify higher-risk patients for adverse outcomes.

Snyder et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark